Ma WW, et al. - Researchers studied 29 candidates to ascertain the maximum tolerated dose (MTD), safety and pharmacokinetic profile of dovitinib combined with gemcitabine and capecitabine in subjects with advanced pancreatic as well as biliary tract cancers and solid malignancies. They noticed one candidate with dose-limiting grade 3 colitis and two with clinically significant neuropathy after the first cycle who wanted a change in dosing. They observed frequent grade 2 or worse adverse effects like fatigue (45%), neutropenia (41%), thrombocytopenia (34%), anemia (24%), nausea (24%), and palmar-plantar erythrodysaesthesia syndrome (21%). No drug-drug interaction between the three medicines was observed. They noted an increment in fibroblast growth factor 23 plasma level in four of five cases during the first cycle of treatment. They preferred dovitinib 300 mg daily in combination with gemcitabine and capecitabine to reach a clinically relevant plasma concentration, which resulted in promising effectiveness in advanced pancreatic cancer.